AI product management · Industry brief

Medical AI is escaping the regulatory net.

A new framework from the journal Nature Communications flags a critical gap in EU oversight: adjunct AI medical products (AMPs)—AI-driven technologies entering healthcare markets without sufficient classification or safety rules [Quelle: NIH/PMC]. The 2024 AI Act and revised Product Liability Directive establish general safety rules, but sector-specific medical device regulations (MDR, IVDR) leave gray zones where AI tools that advise clinicians—but do not directly control devices—fall through oversight cracks. Vendors exploit these gaps by redesigning products to avoid medical device classification.

Expect the Commission to close these loopholes by Q1 2027, reshaping product strategy for vendors in the space.

Financial institutions face a product pivot no one is ready for.

FICO's VP of AI Product Management warns that banks layering agentic AI onto decades of algorithmic decision-making must prepare for a world where customer-owned AI agents negotiate terms, dispute decisions, and route payments autonomously [Quelle: FinTech Profile]. Banks cannot control what agents their customers deploy; they must design APIs and approval workflows that accommodate autonomous negotiation without requiring human intervention at scale. The product challenge: building decisioning systems transparent and contestable enough for AI agents to audit and challenge in real time.

Expect banks to announce agent-compatible decisioning frameworks within the next two quarters.